Sarah Sammons, Breast Medical Oncologist and Senior Physician at Dana-Farber’s Breast Oncology Center, shared a post on LinkedIn:
“The HER2+ metastatic breast cancer landscape continues to evolve.
Beyond the rise of potent ADCs and tucatinib-based regimens, we’re also seeing more intentional integration of endocrine therapy and CDK4/6 inhibition in ER+/HER2+ disease, including palbociclib as part of maintenance strategies.
Key shifts reflected here:
- T-DXd moving earlier in the disease course
- Tucatinib-based regimens reshaping care, particularly for CNS disease
- Selective use of palbociclib with endocrine therapy in ER+/HER2+ patients to extend chemotherapy-free intervals
- Growing emphasis on sequencing, tolerability, and patient-centered goals
As outcomes improve, our challenge is no longer drug availability—but choosing the right sequence for the right patient.”
More posts on Breast Cancer.